CORRECTION article

Front. Cell Dev. Biol.

Sec. Cancer Cell Biology

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1646699

Correction: ELOVL2 Mediated Stabilization of AR Contributes to Enzalutamide Resistance in Prostate Cancer

Provisionally accepted
Jinpeng CenJinpeng Cen1Jiading GuoJiading Guo2Xianzi ZengXianzi Zeng3Xianlu SongXianlu Song2Shengdong GeShengdong Ge1Mingkun ChenMingkun Chen4Qianyi LiQianyi Li5Yu-Zhong YuYu-Zhong Yu1*Dao-Jun LvDao-Jun Lv6*Shan-Chao ZhaoShan-Chao Zhao1,3*
  • 1Southern Medical University Nanfang Hospital, Guangzhou, China
  • 2Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
  • 3The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, China
  • 4The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • 5Southern Medical University, Guangzhou, China
  • 6The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

This article is a correction to:

  1. ELOVL2 Mediated Stabilization of AR Contributes to Enzalutamide Resistance in Prostate Cancer

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

In the published article, there was an error in the legend for Figure 3E. Due to an oversight, the IC50 value for LNCaP-NC was incorrectly reported as: "LNCaP-NC: 21.03 µM, 95% CI: 19.62-22.36."The corrected legend appears below. "LNCaP-NC: 51.15 µM, 95% CI: 47.92-54.33."The authors apologize for this error and confirm that it does not affect the scientific conclusions of the article. The original article has been updated accordingly.In the published article, there was an error in Figure 3E as presented. The visualization results for Figure 3E were correctly submitted and approved during the first round of revisions. However, due to an oversight on our part, this figure was inadvertently omitted in the second revised version. The corrected Figure 3E and its accompanying caption-[FIGURE 3 ELOVL2 inhibition suppresses growth and restores enzalutamide sensitivity in resistant PCa cells]-are provided below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: ELOVL2, enzalutamide resistance, androgen receptor, prostate cancer, crpc

Received: 13 Jun 2025; Accepted: 16 Jun 2025.

Copyright: © 2025 Cen, Guo, Zeng, Song, Ge, Chen, Li, Yu, Lv and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yu-Zhong Yu, Southern Medical University Nanfang Hospital, Guangzhou, China
Dao-Jun Lv, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Shan-Chao Zhao, Southern Medical University Nanfang Hospital, Guangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material